Surge, a San Francisco, CA- and Paris, France-based biotech and medical AI company, raised €2.5M in funding.
The round was led by HCVC, with participation from Boutique Venture, and Nicolas Godin.
The company intends to use the funds to further develop its team and conduct clinical studies with other hospitals, such as the one started in the spring of 2022 with the Foch Hospital in Suresnes, France.
Led by CEO Julien Hédou, Surge is a biotech company focused on optimizing treatment for patients undergoing surgery. Its multidisciplinary team has developed a test to identify patients at risk for complications. The product predicts a patient’s risk of postoperative infections with accuracy, supplying surgeons with the knowledge to guide their clinical decisions (e.g., pre-, intra-, and postoperative patient care optimization) and giving patients access to essential information about their own health.
FinSMEs
26/09/2022